Compare GNL & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNL | AGIO |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | GNL | AGIO |
|---|---|---|
| Price | $9.36 | $27.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $9.50 | ★ $37.63 |
| AVG Volume (30 Days) | ★ 1.8M | 742.0K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | ★ 8.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $75.68 |
| Revenue Next Year | N/A | $167.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $22.24 |
| 52 Week High | $10.04 | $46.00 |
| Indicator | GNL | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 47.00 |
| Support Level | $9.28 | $26.40 |
| Resistance Level | $9.66 | $29.49 |
| Average True Range (ATR) | 0.21 | 1.16 |
| MACD | -0.06 | -0.16 |
| Stochastic Oscillator | 28.47 | 29.40 |
Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.